Clinical Trials Browser

Phase 3 × Esophageal Neoplasms × apatinib × Clear all

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms